PMID- 37539011
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230805
IS  - 2296-2360 (Print)
IS  - 2296-2360 (Electronic)
IS  - 2296-2360 (Linking)
VI  - 11
DP  - 2023
TI  - Case report: Clinicopathological and molecular characteristics of pediatric-type 
      follicular lymphoma.
PG  - 1205384
LID - 10.3389/fped.2023.1205384 [doi]
LID - 1205384
AB  - Pediatric-type follicular lymphoma (PTFL) is a rare pediatric-type indolent 
      B-cell lymphoma that clinicopathologically differs from adult lymphoma. Accurate 
      diagnosis of PTFL, which is often challenging, is essential to avoid missed 
      diagnosis, misdiagnosis, and overtreatment. To improve our understanding of PTFL, 
      clinicopathological features, differential diagnosis, and molecular mutation 
      characteristics of four patients of PTFL were analyzed using hematoxylin and 
      eosin staining, immunohistochemistry, polymerase chain reaction, fluorescence in 
      situ hybridization (FISH), and next-generation sequencing (NGS). A relevant 
      literature review was also performed. All four PTFL patients were male, with ages 
      of 6, 18, 13, and 15 years, and had St. Jude stage I or III. Microscopic results 
      showed that the structure of the lymph nodes was destroyed; the tumor follicles 
      were enlarged and irregular; medium-large blastoid cells with a consistent shape 
      were visible in tumor follicles, and the nucleus was round or oval; and the 
      "starry sky" pattern was easily observed. Tumor cells expressed CD20, PAX-5, 
      BCL6, and CD10. None of the tumor cells expressed BCL2, CD3, CD5, MUM1, and 
      CyclinD1. CD21 showed dilated growth of a follicular dendritic cell network in 
      tumor follicles. EBER genes were negative in all cases. FISH testing also showed 
      negative BCL2 gene breaks and IRF4 gene breaks in all cases. NGS detected 12 
      related mutant genes, including KMT2D, CD79B, GNA13, MYD88, PCLO, TCF3, IRF8, 
      MAP2K1, FOXO1, POLE, INPP5D, and FAT4. Two of the four patients had an IRF8 gene 
      mutation, and one patient had a dual mutation of the MAP2K1 gene. Our study 
      revealed the unique clinicopathological features and molecular mutational 
      characteristics of PTFL, consolidated our understanding of PTFL, and identified 
      other rare mutant genes, which may further contribute to the study of the 
      molecular mechanism and differential diagnosis of PTFL.
CI  - (c) 2023 Ren, Chen, Bai, Zheng, Chang, Jiang, Xia and Zhang.
FAU - Ren, Beibei
AU  - Ren B
AD  - Department of Pathology, Affiliated Cancer Hospital of Zhengzhou University, 
      Zhengzhou, China.
AD  - Henan Medical Key Laboratory of Tumor Pathology and Artificial Intelligence 
      Diagnosis, Zhengzhou, China.
AD  - Pathological Diagnostic Antibody Engineering Research Center of Henan Province, 
      Zhengzhou, China.
FAU - Chen, Yu
AU  - Chen Y
AD  - Department of Pathology, Affiliated Cancer Hospital of Zhengzhou University, 
      Zhengzhou, China.
AD  - Henan Medical Key Laboratory of Tumor Pathology and Artificial Intelligence 
      Diagnosis, Zhengzhou, China.
AD  - Pathological Diagnostic Antibody Engineering Research Center of Henan Province, 
      Zhengzhou, China.
FAU - Bai, Xuanye
AU  - Bai X
AD  - Department of Pathology, Affiliated Cancer Hospital of Zhengzhou University, 
      Zhengzhou, China.
AD  - Henan Medical Key Laboratory of Tumor Pathology and Artificial Intelligence 
      Diagnosis, Zhengzhou, China.
AD  - Pathological Diagnostic Antibody Engineering Research Center of Henan Province, 
      Zhengzhou, China.
FAU - Zheng, Jiawen
AU  - Zheng J
AD  - Department of Molecular Pathology, Affiliated Cancer Hospital of Zhengzhou 
      University, Zhengzhou, China.
FAU - Chang, Jing
AU  - Chang J
AD  - Medical Service Office, Affiliated Cancer Hospital of Zhengzhou University, 
      Zhengzhou, China.
FAU - Jiang, Xiangnan
AU  - Jiang X
AD  - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, 
      China.
FAU - Xia, Qingxin
AU  - Xia Q
AD  - Department of Pathology, Affiliated Cancer Hospital of Zhengzhou University, 
      Zhengzhou, China.
AD  - Henan Medical Key Laboratory of Tumor Pathology and Artificial Intelligence 
      Diagnosis, Zhengzhou, China.
AD  - Pathological Diagnostic Antibody Engineering Research Center of Henan Province, 
      Zhengzhou, China.
FAU - Zhang, He
AU  - Zhang H
AD  - Department of Pathology, Affiliated Cancer Hospital of Zhengzhou University, 
      Zhengzhou, China.
AD  - Henan Medical Key Laboratory of Tumor Pathology and Artificial Intelligence 
      Diagnosis, Zhengzhou, China.
AD  - Pathological Diagnostic Antibody Engineering Research Center of Henan Province, 
      Zhengzhou, China.
LA  - eng
PT  - Case Reports
DEP - 20230719
PL  - Switzerland
TA  - Front Pediatr
JT  - Frontiers in pediatrics
JID - 101615492
PMC - PMC10394512
OTO - NOTNLM
OT  - Immunohistochemistry
OT  - NGS
OT  - follicular lymphoma
OT  - molecular
OT  - pediatric type follicular lymphoma
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/08/04 06:43
MHDA- 2023/08/04 06:44
PMCR- 2023/07/19
CRDT- 2023/08/04 04:09
PHST- 2023/04/13 00:00 [received]
PHST- 2023/06/30 00:00 [accepted]
PHST- 2023/08/04 06:44 [medline]
PHST- 2023/08/04 06:43 [pubmed]
PHST- 2023/08/04 04:09 [entrez]
PHST- 2023/07/19 00:00 [pmc-release]
AID - 10.3389/fped.2023.1205384 [doi]
PST - epublish
SO  - Front Pediatr. 2023 Jul 19;11:1205384. doi: 10.3389/fped.2023.1205384. 
      eCollection 2023.